PRA 023 companion diagnostic - Merck & Co
Alternative Names: PRA023 companion diagnostic - Merck & CoLatest Information Update: 20 Jun 2023
At a glance
- Originator Prometheus Biosciences
- Developer Merck & Co
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Crohn's disease; Systemic scleroderma; Ulcerative colitis
Most Recent Events
- 16 Jun 2023 Prometheus Biosciences has been acquired and merged into Merck & Co
- 08 Jun 2022 Prometheus Biosciences completes enrolment in its phase-II clinical trials in Crohn's disease in Australia, Belgium, Czech Republic, France, Georgia, Poland, Canada, USA (IV) (NCT05013905)
- 24 May 2022 Prometheus Biosciences withdraws its phase-II clinical trials in Crohn's disease in Ukraine (IV) before enrolment (NCT05013905)